California 2019-2020 Regular Session

California Assembly Bill AB1803

Introduced
2/28/19  
Introduced
2/28/19  
Refer
3/21/19  
Refer
3/21/19  
Report Pass
4/24/19  
Report Pass
4/24/19  
Refer
4/24/19  
Refer
4/24/19  
Report Pass
5/1/19  
Engrossed
5/9/19  
Engrossed
5/9/19  
Refer
5/9/19  
Refer
5/9/19  
Refer
5/22/19  
Refer
5/22/19  
Report Pass
6/12/19  
Report Pass
6/12/19  
Refer
6/12/19  
Enrolled
7/1/19  
Enrolled
7/1/19  
Chaptered
7/12/19  
Chaptered
7/12/19  
Passed
7/12/19  

Caption

Pharmacy: health care coverage: claims for prescription drugs sold for retail price.

Impact

The immediate impact of AB 1803 is that it introduces a provision that allows pharmacies to simplify the claims process for customers who pay out-of-pocket for their medications. By ensuring that pharmacies inform customers of better pricing options, the bill aims to enhance customer transparency and potentially reduce out-of-pocket expenses for those who may otherwise be misled by complex insurance arrangements. Given its urgency status, the bill took effect immediately upon governor approval, thus streamlining pharmacy operations and insurance claims within a short timeframe.

Summary

Assembly Bill 1803, known as the Pharmacy: Health Care Coverage: Claims for Prescription Drugs Sold for Retail Price, is a legislative measure aimed at amending California's Pharmacy Law. The bill seeks to change the requirements for pharmacies when informing customers about the costs of covered prescription drugs. Specifically, pharmacies will now be required to inform customers at the point of sale if the retail price of their medication is lower than the applicable cost-sharing amount. Additionally, if a customer opts to pay the retail price, the bill mandates that the pharmacy submit this claim to the customer's health care service plan or insurer.

Sentiment

The sentiment surrounding AB 1803 appears to be generally positive among legislators and stakeholders in the health care sector. Proponents argue that reforming the claims process is a step towards improving patient access and affordability of medications. The legislative discussion highlighted the need for greater transparency in the retail pricing of prescription drugs, which is a growing concern among consumers. This change has been acknowledged as necessary, particularly in addressing patient financial burdens.

Contention

Despite the positive momentum, there are concerns regarding the implementation of these new requirements, especially as they relate to the preparedness of pharmacies and health care plans to adapt swiftly to the changes. Critics express uncertainty about how effectively pharmacies can handle the additional responsibilities and whether this will lead to increased administrative costs that could cut into their margins. Overall, while the bill enjoys considerable support, the transition phase remains an area of contention among pharmacy representatives.

Companion Bills

No companion bills found.

Similar Bills

CA AB2863

Health care coverage: prescriptions.

CA AB315

Pharmacy benefit management.

DE HB383

An Act To Amend Titles 18 And 24 Of The Delaware Code Relating To Prohibiting Discrimination Against 340b Drugs And Covered Entities By Manufacturers And Pharmacy Benefits Managers.

CA AB933

Prescription drug cost sharing.

NJ S3604

Authorizes use of healthcare platforms providing discounted prices for payment of prescription and non-prescription drugs or devices and for telehealth and telemedicine services.

NJ A5212

Authorizes use of healthcare platforms providing discounted prices for payment of prescription and non-prescription drugs or devices and for telehealth and telemedicine services.

LA HB547

Prohibits penalties for disclosure by pharmacists of certain prescription drug cost information

HI HB1083

Relating To The Repeal Of Section 328-106, Hawaii Revised Statutes.